CM
JANX icon

Caption Management’s Janux Therapeutics JANX Stock Holding History

Caption Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-500,000
Closed -$6.9M – 1805
2025
Q4 		$6.9M Buy
+500,000
New +$11.8M 0.05% 421
2025
Q3 		– Sell
-500,700
Closed -$11.6M – 1850
2025
Q2 		$11.6M Buy
500,700
+464,700
+1,291% +$12.2M 0.13% 173
2025
Q1 		$972K Buy
36,000
+35,900
+35,900% +$1.35M 0.01% 925
2024
Q4 		$5.35K Buy
+100
New +$5.29K ﹤0.01% 1410

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Caption Management's JANX Position: Q2 2026 in Review

Caption Management sold out of Janux Therapeutics (JANX) in Q2 2026, closing a stake of 1,488 shares — an estimated $21.6K sold.

Caption Management first reported a position in JANX in Q4 2024 and held it in 6 quarters. The position peaked at $10.6M in Q2 2025. 197 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Caption Management reported no remaining Janux Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Caption Management sold 1,488 Janux Therapeutics shares in Q2 2026, an estimated $21.6K.
  • Caption Management first reported a position in Janux Therapeutics in Q4 2024 and held it in 6 quarters.
  • Caption Management's Janux Therapeutics position peaked at $10.6M in Q2 2025.
  • 197 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.